Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs Twist Bioscience Corp — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $96.71, while Twist Bioscience Corp trades at $124.51 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TLH | TWST | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $105.36 | $124.88 |
52-Week Low | $96.39 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH trades at $96.86, up 0.49% today, but technical indicators signal a bearish trend with moving averages and ADX pointing downward. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent corporate actions include consistent dividend payments, with the latest being $0.38 per share scheduled for August 2026. Market sentiment is influenced by broader economic factors like rising Treasury yields and oil price volatility, as highlighted in recent financial news.
The outlook for TLH is cautious due to weak technical momentum and absent key financial metrics, though dividend stability offers some support. Risks include macroeconomic pressures from potential Fed rate hikes and inflation. Investors should seek updated earnings reports for fundamental reassessment, as current data gaps hinder a full evaluation of growth prospects or valuation attractiveness.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
